BMN 110 US Expanded Access Program

ClinicalTrials.gov ID: NCT01858103

Public ClinicalTrials.gov record NCT01858103. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-label BMN 110 US Expanded Access Program (BMN 110 US EAP) to Provide BMN 110 to Patients Diagnosed With MPS IVA

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The Expanded Access Program (EAP) is an open-label, multicenter program to: 1. Provide patients who have been diagnosed with Mucopolysaccharidosis IVA (MPS IVA) access to BMN 110 until commercial product is available 2. Collect additional information on the safety and tolerability of BMN 110 administration in patients with MPS IVA Patients enrolled in the EAP will receive 2.0 mg/kg intravenous infusions of BMN 110 every week during the program.

Study identification

NCT ID: NCT01858103
Recruitment status: Approved For Marketing
Study type: Expanded access
Phase: Not listed
Lead sponsor: BioMarin Pharmaceutical; Industry
Enrollment: Not listed

Conditions and interventions

Conditions

Interventions

BMN 110 Drug

Drug

Eligibility (public fields only)

Age range: Not listed
Sex: All
Healthy volunteers: Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Not listed
Primary completion: Not listed
Completion: Not listed
Last update posted: Apr 2, 2014

United States locations

U.S. sites: 24
U.S. states: 19
U.S. cities: 24

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35294	—
Not listed	Little Rock	Arkansas	72202	—
Not listed	Oakland	California	94609	—
Not listed	Orange	California	—	—
Not listed	Aurora	Colorado	—	—
Not listed	Washington D.C.	District of Columbia	20010	—
Not listed	Hollywood	Florida	33021	—
Not listed	Miami	Florida	—	—
Not listed	Atlanta	Georgia	30033	—
Not listed	Chicago	Illinois	60611	—
Not listed	Louisville	Kentucky	—	—
Not listed	New Orleans	Louisiana	—	—
Not listed	Minneapolis	Minnesota	55404	—
Not listed	Paterson	New Jersey	—	—
Not listed	Manhasset	New York	11030	—
Not listed	New York	New York	—	—
Not listed	Portland	Oregon	97239	—
Not listed	Philadelphia	Pennsylvania	—	—
Not listed	Pittsburgh	Pennsylvania	15224	—
Not listed	Nashville	Tennessee	—	—
Not listed	Houston	Texas	—	—
Not listed	Salt Lake City	Utah	84113	—
Not listed	Seattle	Washington	—	—
Not listed	Tacoma	Washington	98405	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01858103, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 2, 2014 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01858103 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →